ki-eis-fund - o2h Ventures

as seen on

fund highlights

Therapeutics, or coming up with the next life-saving drug requires going through vast quantities of data and making various calculated guesses on how the human body will behave, this costs millions and often billions. AI has the potential to help make sense of this data in that it helps to see patterns and the AI will help make smarter predictions on how to deploy resources on research and experiments.

Access to the most exciting scientific ideas through its live grassroots working relationships in the biotech community for over 20 years.
Operating from their proprietary 2.7 acre Mill SciTech Park the fund can incubate life science companies leading to more effective decision making.
The fund is structured to be EIS compliant providing income, inheritance and capital gains tax breaks for UK taxpayers.

About o2h ventures

fund overview

Minimum Investment

£25k

Target Return

IRR 20%

Fund Size	Target £ 10m
Tax Advantages	Under new "Approved EIS funds" investor are eligible for added tax advantages. A carry-back rule enable investors to set their relief against income tax liabilities in the year before the fund closes.
Diversification	Aim to build investors an initial Portfolio of 5-10 unquoted and/or AIM-listed companies.
Tax Relief	30% income tax relief *
Differentiation	Two part investment focus of Access & Incubation, providing unique opportunities and reducing investment risk by being deeply involved.

For more details on the fund, please download fund documents

Request Prospectus

For more details on the fund, please download fund documents

Request Prospectus

EIS tax relief is very attractive for UK tax payers

You invest £50k

EIS gives you £15k tax relief from HMRC

EIS gives you £25k tax relief from HMRC

COMPANY VALUE DOUBLES

Investment now worth £100k

£50k profit

+ £15k income tax relief

- £10k performance incentive

= £55k net profit

VALUE STAYS THE SAME

Investment still worth £50k

£0 profit

+ £15k income tax relief

- £0 performance incentive

= £15k net profit

COMPANY FAILS

Investment now worth £0

£50k loss

+ £15k income tax relief

+ £15,750 loss relief *

- £0 performance incentive

= £19,250 capital loss

* Loss relief calculated on higher rate tax bracket Worked example is net of any fund fees

Need help in understanding how investing in EIS works?

Contact Support Team

Need help in understanding how investing in EIS works?

Contact Support Team

our team

Sunil Shah

Chief Executive Officer

Sunil's Biography

Sunil Shah

Chief Executive Officer

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil co-founded o2h ventures which involves discovery services / collaborations, seeding drug discovery, academic in-licensing and biotechnology incubation. Sunil has a degree in Biochemistry and an MBA from Cambridge University

Prashant Shah

Director

Prashant's Biography

Prashant Shah

Director

A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management.

Andy Morley

Chief Scientific Officer

Andy's Biography

Andy Morley

Chief Scientific Officer

Creative and innovative medicinal chemist with extensive knowledge and expertise. Twenty five years experience working in the pharmaceutical industry.

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine Beech Biography

Catherine Beech

Independent Representative to the Investment Advisory Panel

Catherine has over 25 years of experience in biotech, pharmaceutical and as a venture investor. She is currently the CEO of Exonate for which she was one of the founders leading the spin-out from Nottingham University. Catherine has a degree in medicine from Birmingham University and in 2008 was awarded the OBE for services to technology and innovation.

See All

portfolio